Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - Cervarix, October 24, 2008

System Info - 94739  SHONE, DEANNA   20-May-2009 17:28:49  SHONEDE


Submission Type: Original Application   Submission ID:  125259/0    Office: OVRR  


Human Papillomavirus Vaccine, AS04 Adjuvant-Adsorbed


GlaxoSmithKline Biologicals          

Telecon Date/Time:  24-OCT-2008 12:00 AM               Initiated by FDA?  Yes

Telephone Number:    

Communication Categorie(s):



Telecon Summary:

CBER Statistical comments in response to GSK's 29-Sep-2008 HPV-008 RAP submission to the BLA.

FDA Participants:  

Non-FDA Participants:   

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:

 From:                     Gemignani, Helen S 

Sent:                      Friday, October 24, 2008 1:34 PM

To:                          ''

Cc:                          'Cynthia.A.D''

Subject:                Comments on 9/29/08 BLA Submission

Following are some statistical comments RE: September 29, 2008, HPV-008 RAP submission to the BLA. Please let me know if you have any questions or need additional clarification.

1) There are more than 30 exploratory objectives to be evaluated in the Reporting and Analysis Plan for efficacy for HPV-008. In these analyses, Type I errors are not adjusted for multiple comparisons. Please acknowledge that results based on these analyses cannot be used to support post-licensure supplements for labeling changes.

2) Please refer to page 38, section 4.5.3. Given that the number of breakthrough cases will not be large, too many covariates presented in the Cox regression models may cause over-adjustment. In addition, collinearity between covariates may emerge. Please comment.

3) Please note some minor editing changes to be made on page 13: Please add “HRW (=High-risk (oncogenic) HPV types without HPV-16 or HPV-18: HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68)” in the fourth paragraph

Helen Sullivan Gemignani

Regulatory Project Manager

Division of Vaccines and Related Products Applications

Office of Vaccines Research and Review

Center for Biologics Evaluation and Research

Food and Drug Administration

phone: (301) 827-3070

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.

Page Last Updated: 04/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English